MATERIAL AND METHODS: Thirty type 2 diabetic and 11 healthy subjects with LDL levels between 100-160 mg/dl. without a history of cardiovascular event were included in the study. Both groups were matched with respect to age, gender, body mass indices and lipid levels. Flow- mediated dilatation (endothelium dependent, FMD) and nitroglycerine-induced dilatation (endothelium independent, NID) were measured in the brachial artery using high-resolution ultrasound in all participants and carotid artery intima media thickness (IMT) were also evaluated. OxLDL levels, lipid parameters, blood glucose, C-peptide, HbA1c and inflammatory markers including C-reactive protein (CRP), fibrinogen, erythrocyte sedimentation rate (ESR) were studied. Type 2 diabetic patients received 10 mg. Atorvastatin for 6 weeks and FMD and NID were reevaluated and oxLDL levels and inflammatory markers remeasured
材料和方法:选择低密度脂蛋白水平在100 - 160毫克/ dl不伴心血管疾病的30例2型糖尿病患者和11个健康的受试者。两组在年龄、性别、体重指数、血脂水平匹配。在肱动脉用超声 测所有参与者的FMD和NID 水平同时评估颈动脉内膜厚度、低密度脂蛋白水平OxL、DL水平、脂质参数、血糖、c -肽,血红蛋白和炎症标志物包括c反应蛋白(c)、纤维蛋白原、红血球沉降速率(ESR)。2型糖尿病患者用10毫克的阿托伐他汀治疗。阿托伐他汀治疗6周,再次评估FMD、 NID和 氧化型低密度脂蛋白水平。